Welcome to our dedicated page for Sobr Safe news (Ticker: SOBR), a resource for investors and traders seeking the latest updates and insights on Sobr Safe stock.
SOBR Safe, Inc. (Nasdaq: SOBR) is a developer of next-generation alcohol monitoring and detection technology, and its news flow reflects both technology milestones and capital markets activity. The company focuses on transdermal, touch-based alcohol detection that reports in real time through a cloud-based data platform, with applications in behavioral health, family law, consumer markets and related safety and compliance contexts.
On this page, readers can follow SOBRsafe news such as quarterly financial and operating results, where the company reports revenue trends, gross margin, operating expenses and net loss, along with commentary on device deployments and software subscription growth. Earnings releases also highlight the contribution of SOBRsure GEN 2 hardware and software to total revenue and the evolution of annual recurring revenue from subscription sales.
SOBRsafe’s news also covers product and technology developments, including independent third-party validation of the SOBRsure GEN 2 device, enhancements to its mobile application and software platform, and intellectual property updates such as the granting of a European Patent for the SOBRcheck device. Corporate updates describe marketing initiatives, conference participation, sales efforts in behavioral health and family law markets, and organizational changes, including board appointments and additions to the leadership team.
Investors can also track financing announcements, such as private placements of common stock and warrants, and related use of proceeds for working capital and general corporate purposes. For anyone monitoring SOBR stock, this news feed provides a centralized view of the company’s reported progress in technology validation, market outreach, subscription growth and capital structure. Bookmark this page to review new press releases, regulatory disclosures referenced in 8-K filings and other company communications as they are issued.
SOBRsafe (NASDAQ: SOBR) has released a comprehensive survey revealing significant insights about alcohol consumption among middle-aged American women. The Censuswide study of 1,001 women aged 40-65 shows that 30% are moving toward sober living while 45% express concerns about dependency.
The survey highlights concerning trends among women in their 40s:
- 28% drink more than in their 20s
- Over 1/3 use alcohol for anxiety management
- 28% increased drinking after breakups
- 40% of single women use alcohol for first-date anxiety
The study also reveals health impacts: 32% report gut health issues, 27% experience disrupted sleep, and 23% face memory issues. Major barriers to seeking help include embarrassment (18%), reluctance to quit (32%), and financial limitations (16%). The research coincides with the U.S. Surgeon General's warning about alcohol-cancer links and Alcohol Awareness Month.
SOBRsafe (NASDAQ:SOBR) has announced a 1-for-10 reverse stock split of its common stock, effective April 4, 2025. The split will reduce outstanding shares from approximately 15,161,445 to 1,516,145 shares. Trading will continue under the symbol 'SOBR' with a new CUSIP number 833592 405.
The reverse split, approved by shareholders on December 9, 2024, will apply equally to all outstanding shares, with stockholders maintaining their same percentage ownership except for minor adjustments from fractional shares. Fractional shares will be rounded up to the nearest whole number. All securities including warrants and equity compensation awards will be proportionately adjusted.
Equiniti Trust Company is serving as the exchange agent. Stockholders with electronic book-entry shares require no action, while those holding certificates will receive instructions for exchanging their shares.
SOBRsafe (NASDAQ:SOBR) and Orbiit have announced a strategic AI partnership to enhance alcohol recovery solutions. The collaboration combines SOBRsafe's transdermal alcohol detection wristband with Orbiit's AI-powered engagement platform to provide comprehensive support for individuals managing sobriety.
The partnership addresses a significant market need, as over 28 million Americans suffered from Alcohol Use Disorder (AUD) in 2023, with only 15.6% receiving treatment. The solution integrates three key components: the SOBRsure Band for continuous alcohol detection, AI-Powered Orbie for 24/7 support, and SMS accountability messaging.
The Orbiit Recovery Program is priced at $3,995 for a six-month program, including the SOBRsure band and full access to Orbiit's AI platform. The program combines wearable technology with behavioral science principles to enhance accountability, motivation, and long-term recovery success.
SOBR Safe Inc (NASDAQ:SOBR) has launched SOBRsure, a new wristband device that detects alcohol through skin contact using transdermal technology. The device retails for $249 with subscription options of $39.99/month (BASIC) or $59.99/month (PLUS). Key features include real-time alcohol detection, GPS tracking, instant alerts, and historical reporting capabilities.
The water-resistant wristband resembles a fitness tracker and will begin shipping by end of November 2024. It's designed to support sobriety monitoring for individuals, families, and businesses, particularly in high-risk industries like transportation and construction. The system includes an enhanced app experience and provides continuous feedback for maintaining accountability.
SOBRsafe (NASDAQ:SOBR) announced it has regained compliance with Nasdaq's listing requirements, including minimum bid price, public float, and stockholders' equity rules. The company will continue trading on The Nasdaq Capital Market under 'SOBR'. Following the October 30, 2024 compliance letter, SOBRsafe enters a mandatory one-year monitoring period. If found non-compliant with the Equity Rule during this period, the company will face immediate delisting procedures without a cure period, though it may request a new hearing.
SOBRsafe, Inc. (NASDAQ:SOBR) has launched a fully-integrated enterprise software solution for alcohol detection and monitoring in behavioral health settings. The platform combines SOBRcheck™ for point-of-care screening and SOBRsure™ for continuous monitoring, offering real-time visibility across multiple users and locations in one dashboard.
Key features include:
- Touch-based transdermal alcohol detection, eliminating need for breath, blood, or urine samples
- Instant reporting accessible via computer or mobile device
- Integration with electronic medical records (EMR)
- Robust lookback capabilities for demonstrating compliance
This innovative solution aims to transform how behavioral health providers monitor alcohol use, enhance responsiveness, reduce recidivism, and improve patient outcomes in addiction and alcohol use disorder (AUD) treatment.
SOBR Safe, Inc. (NASDAQ:SOBR) has successfully completed a private placement of $8.2 million, with Aegis Capital Corp. acting as the exclusive placement agent. This financial transaction, announced on October 9, 2024, represents a significant capital raise for the company. The private placement structure suggests that the shares were offered to a select group of investors rather than the general public.
While the press release does not provide details on the specific use of funds or the terms of the placement, such capital raises are typically used to support company growth, fund research and development, or strengthen the balance sheet. For SOBR Safe, this injection of capital could potentially accelerate its business initiatives and enhance its market position.
SOBRsafe (NASDAQ:SOBR), a provider of transdermal alcohol detection solutions, has closed a private placement with institutional investors, raising $8.2 million in gross proceeds. The company issued 2,024,691 units at $4.05 per unit, each consisting of one share of common stock (or pre-funded warrant) and multiple warrants. The Series A warrants are exercisable at $3.80 per share with a 5-year term, while the Series B warrants have a nominal exercise price. Both warrant series are subject to adjustments. Aegis Capital Corp. acted as the exclusive placement agent. The funds will be used for general corporate purposes and working capital. SOBRsafe has agreed to file registration statements for the resale of the securities.
SOBRsafe (NASDAQ:SOBR), a provider of transdermal alcohol detection solutions, has announced the pricing of a $8.2 million private placement with institutional investors. The company plans to issue 2,024,691 units at $4.05 per unit, each consisting of one common stock share (or pre-funded warrant) and multiple warrants. The Series A warrants are exercisable at $3.80 per share, while the Series B warrants have a $0.001 exercise price.
The private placement is expected to close around October 8, 2024, subject to customary conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent. SOBRsafe intends to use the net proceeds for general corporate purposes and working capital. The company has agreed to file registration statements with the SEC for the resale of the securities issued in this private placement.
SOBRsafe, a provider of transdermal alcohol detection solutions, has announced international expansion opportunities in India, Italy, and Australia/New Zealand. In India, a critical infrastructure developer has selected SOBRcheck™ for a paid proof-of-concept installation in a public facility. In Italy, a global employer with a fleet of over 10,000 vehicles in Europe has chosen SOBRsure™ wristbands for fleet drivers. In Australia and New Zealand, courts have approved SOBRsafe's technology for use in family law cases, opening up marketing opportunities to over 7,000 family law attorneys in the region.
CEO Dave Gandini highlighted the importance of these developments, noting the high rate of alcohol dependence in India, the EU's "Vision Zero" initiative for road safety, and the potential for expansion into the U.S. family law vertical. The company plans to evaluate the potential for strategic international expansion at the end of Q1 2025 based on the outcomes of these opportunities.